A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: placebo
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Akeso
- Target Recruit Count
- 198
- Registration Number
- NCT06767540
- Locations
- 🇨🇳
The Second Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Chongqing Traditional Chinese Medicine Hospital, Chongqing, Chongqing, China
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Akeso
- Target Recruit Count
- 24
- Registration Number
- NCT06756126
- Locations
- 🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳The University of Hong Kong - Shenzhen Hospital, Shenzhen, Guangdong, China
A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 100
- Registration Number
- NCT06730386
- Locations
- 🇦🇺
Blacktown Hospital-Blacktwon Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇦🇺Macquarie University, North Ryde, New South Wales, Australia
🇦🇺ICON Cancer Centre South Brisbane, South Brisbane, Queensland, Australia
A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Akeso
- Target Recruit Count
- 450
- Registration Number
- NCT06700499
- Locations
- 🇨🇳
Changde First People's Hospital, Changde, Hunan, China
🇨🇳XiangYa Hospital CentralSouth University, Changsha, Hunan, China
🇨🇳Yueyang Central Hospital, Yueyang, Hunan, China
AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Akeso
- Target Recruit Count
- 87
- Registration Number
- NCT06691360
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
- Conditions
- Platinum-sensitive Ovarian Cancer
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Akeso
- Target Recruit Count
- 150
- Registration Number
- NCT06686030
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science And Technology, Wuhan, China
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Drug: AK112, Cadonilimab, nab-paclitaxel, gemcitabine
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Akeso
- Target Recruit Count
- 110
- Registration Number
- NCT06646055
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology., Wuhan, Hubei, China
A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Akeso
- Target Recruit Count
- 180
- Registration Number
- NCT06641388
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 280
- Registration Number
- NCT06642792
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
- Conditions
- NSCLC (Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 560
- Registration Number
- NCT06617416
- Locations
- 🇨🇳
Cancer Hospital of Shandong First Medical University, Jinan, China